STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: Results of a phase 1b trial.

Journal for ImmunoTherapy of Cancer

Volumn 6, Issue 1, 2018, Pages

  Reilley, Matthew J ^a   McCoon, Patricia ^b   Cook, Carl ^b   Lyne, Paul ^b   Kurzrock, Razelle ^c   Kim, Youngsoo ^d   Woessner, Richard ^b   Younes, Anas ^e   Nemunaitis, John ^f   Fowler, Nathan ^g   Curran, Michael ^g   Liu, Qinying ^g   Zhou, Tianyuan ^d   Schmidt, Joanna ^d   Jo, Minji ^d   Lee, Samantha J ^d   Yamashita, Mason ^d   Hughes, Steven G ^d   Fayad, Luis ^g   Piha Paul, Sarina ^g   Nadella, Murali V P ^b   Xiao, Xiaokun ^d   Hsu, Jeff ^d   Revenko, Alexey ^d   Monia, Brett P ^d   MacLeod, A Robert ^d   Hong, David S ^g   more..

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d ISIS PHARMACEUTICALS   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f Mary Crowley Cancer Research Centers   (United States)

^g UNIVERSITY OF TEXAS   (United States)

Author keywords

Anti sense oligonucleotide; Clinical trial; Diffuse large B cell lymphoma; DLBCL; Immunotherapy; JAK STAT; Lymphoma; STAT3

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTISENSE OLIGONUCLEOTIDE; ASPARTATE AMINOTRANSFERASE; CREATININE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DANVATIRSEN; INTERFERON REGULATORY FACTOR 4; STAT3 PROTEIN; OLIGONUCLEOTIDE; STAT3 PROTEIN, HUMAN;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER TISSUE; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; CONSTIPATION; DIARRHEA; DISEASE BURDEN; DNA EXTRACTION; DRUG DISPOSITION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DYSPHAGIA; DYSPNEA; FATIGUE; FEMALE; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; GENE REARRANGEMENT; GENE SEQUENCE; GENE TARGETING; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; HYPERTRANSAMINASEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; IMMUNE RESPONSE; IMMUNOMODULATION; JAK-STAT SIGNALING; LARGE CELL LYMPHOMA; LIFE EXPECTANCY; LYMPHOMA; MACROPHAGE; MAINTENANCE DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VERY ELDERLY; VOMITING; X-RAY COMPUTED TOMOGRAPHY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; STAT3 TRANSCRIPTION FACTOR; YOUNG ADULT;

EID: 85056740625     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-018-0436-5     Document Type: Article

References (37)

1. Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science [Internet]. 1994;264(5164):1415-21 Available from: http://www.ncbi.nlm.nih.gov/pubmed/8197455. [cited 21 Nov 2017].
2. Zhong Z, Wen Z, Darnell JE. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science [Internet]. 1994;264(5155):95-8 Available from: http://www.ncbi.nlm.nih.gov/pubmed/8140422. [cited 21 Nov 2017].
3. Lütticken C, Wegenka UM, Yuan J, Buschmann J, Schindler C, Ziemiecki A, et al. Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science [Internet]. 1994;263(5143):89-92 Available from: http://www.ncbi.nlm.nih.gov/pubmed/8272872. [cited 21 Nov 2017].
4. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer [Internet]. 2009;9(11):798-809 Available from: http://www.nature.com/doifinder/10.1038/nrc2734. [cited 21 Nov 2017].
5. Denley SM, Jamieson NB, McCall P, Oien KA, Morton JP, Carter CR, et al. Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma. J Gastrointest Surg [Internet]. 2013;17(5):887-98 Available from: http://link.springer.com/10.1007/s11605-013-2168-7. [cited 21 Nov 2017].
6. Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov [Internet]. 2015;5(3):316-31 Available from: http://cancerdiscovery.aacrjournals.org/cgi/doi/10.1158/2159-8290.CD-14-0736. [cited 21 Nov 2017].
7. Bromberg J, Darnell JE. The role of STATs in transcriptional control and their impact on cellular function. Oncogene [Internet]. 2000;19(21):2468-73 Available from: http://www.nature.com/articles/1203476. [cited 21 Nov 2017].
8. Yu H, Jove R. The STATs of cancer - new molecular targets come of age. Nat Rev Cancer [Internet]. 2004;4(2):97-105 Available from: http://www.nature.com/doifinder/10.1038/nrc1275. [cited 21 Nov 2017].
9. Haura EB, Turkson J, Jove R. Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol [Internet]. 2005;2(6):315-24 Available from: http://www.nature.com/doifinder/10.1038/ncponc0195. [cited 21 Nov 2017].
10. Woodfield SE, Graves HK, Hernandez JA, Bergmann A. De-regulation of JNK and JAK/STAT signaling in ESCRT-II mutant tissues cooperatively contributes to neoplastic tumorigenesis. Singh SR, editor. PLoS One [Internet]. 2013;8(2):e56021 Available from: http://dx.plos.org/10.1371/journal.pone.0056021. [cited 21 Nov 2017].
11. Kroon P, Berry PA, Stower MJ, Rodrigues G, Mann VM, Simms M, et al. JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. Cancer Res [Internet]. 2013;73(16):5288-98 Available from: http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.CAN-13-0874. [cited 21 Nov 2017].
12. McCann GA, Naidu S, Rath KS, Bid HK, Tierney BJ, Suarez A, et al. Targeting constitutively-activated STAT3 in hypoxic ovarian cancer, using a novel STAT3 inhibitor. Oncoscience [Internet]. 2014;1(3):216-28 Available from: http://impactjournals.com/oncoscience/index.php?abs=26. [cited 21 Nov 2017].
13. Kowshik J, Baba AB, Giri H, Deepak Reddy G, Dixit M, Nagini S. Astaxanthin inhibits JAK/STAT-3 signaling to abrogate cell proliferation, invasion and angiogenesis in a hamster model of oral cancer. Singh SR, editor. PLoS One [Internet]. 2014;9(10):e109114 Available from: http://dx.plos.org/10.1371/journal.pone.0109114. [cited 21 Nov 2017].
14. Sen M, Pollock NI, Black J, DeGrave KA, Wheeler S, Freilino ML, et al. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth. Neoplasia [Internet]. 2015;17(3):256-64 Available from: http://linkinghub.elsevier.com/retrieve/pii/S1476558615000147. [cited 21 Nov 2017].
15. Liu Y, Li P-K, Li C, Lin J. Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells. J Biol Chem [Internet]. 2010;285(35):27429-39 Available from: http://www.jbc.org/lookup/doi/10.1074/jbc.M110.142752. [cited 21 Nov 2017].
16. Azare J, Leslie K, Al-Ahmadie H, Gerald W, Weinreb PH, Violette SM, et al. Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6. Mol Cell Biol [Internet]. 2007;27(12):4444-53 Available from: http://mcb.asm.org/cgi/doi/10.1128/MCB.02404-06. [cited 21 Nov 2017].
17. Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor- B pathways in subtypes of diffuse large B-cell lymphoma. Blood [Internet]. 2008;111(7):3701-13 Available from: http://www.ncbi.nlm.nih.gov/pubmed/18160665. [cited 21 Nov 2017].
18. Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res [Internet]. 2002;62(12):3351-5 Available from: http://www.ncbi.nlm.nih.gov/pubmed/12067972. [cited 21 Nov 2017].
19. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res [Internet]. 2002;8(4):945-54 Available from: http://www.ncbi.nlm.nih.gov/pubmed/11948098. [cited 21 Nov 2017].
20. Danoch H, Kalechman Y, Albeck M, Longo DL, Sredni B. Sensitizing B- and T- cell Lymphoma Cells to Paclitaxel/Abraxane-Induced Death by AS101 via Inhibition of the VLA-4-IL10-Survivin Axis. Mol Cancer Res [Internet]. 2015;13(3):411-22 Available from: http://mcr.aacrjournals.org/cgi/doi/10.1158/1541-7786.MCR-14-0459. [cited 21 Nov 2017].
21. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med [Internet]. 2005;11(12):1314-21 Available from: http://www.nature.com/doifinder/10.1038/nm1325. [cited 21 Nov 2017].
22. Li HS, Liu C, Xiao Y, Chu F, Liang X, Peng W, et al. Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells. Sci Signal [Internet]. 2016;9(447):ra94 Available from: http://stke.sciencemag.org/cgi/doi/10.1126/scisignal.aaf3957. [cited 21 Nov 2017].
23. Mace TA, Ameen Z, Collins A, Wojcik S, Mair M, Young GS, et al. Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res [Internet]. 2013;73(10):3007-18 Available from: http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.CAN-12-4601. [cited 21 Nov 2017].
24. Seth PP, Vasquez G, Allerson CA, Berdeja A, Gaus H, Kinberger GA, et al. Synthesis and biophysical evaluation of 2′,4′-constrained 2'O-methoxyethyl and 2′,4′-constrained 2'O-ethyl nucleic acid analogues. J Org Chem [Internet]. 2010;75(5):1569-81 Available from: http://pubs.acs.org/doi/abs/10.1021/jo902560f. [cited 21 Nov 2017].
25. Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med [Internet]. 2015;7(314):314ra185 Available from: http://stm.sciencemag.org/cgi/doi/10.1126/scitranslmed.aac5272. [cited 21 Nov 2017].
26. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol [Internet]. 2013;31(11):1023-31 Available from: http://www.ncbi.nlm.nih.gov/pubmed/24142049. [cited 21 Nov 2017].
27. Ok CY, Chen J, Xu-Monette ZY, Tzankov A, Manyam GC, Li L, et al. Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma. Clin Cancer Res [Internet]. 2014;20(19) Available from: http://clincancerres.aacrjournals.org/content/20/19/5113. [cited 28 July 2017].
28. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature [Internet]. 2010;463(7277):88-92 Available from: http://www.nature.com/doifinder/10.1038/nature08638. [cited 21 Aug 2017].
29. Song TL, Nairismägi M-L, Laurensia Y, Lim J-Q, Tan J, Li Z-M, et al. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. Blood [Internet]. 2018;132(11):1146-58 Available from: http://www.ncbi.nlm.nih.gov/pubmed/30054295. [cited 7 Oct 2018].
30. Manso R, Sánchez-Beato M, González-Rincón J, Gómez S, Rojo F, Mollejo M, et al. Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma. Br J Haematol [Internet]. 2017; Available from: http://www.ncbi.nlm.nih.gov/pubmed/29076126. [cited 7 Oct 2018].
31. Nairismägi M-L, Gerritsen ME, Li ZM, Wijaya GC, Chia BKH, Laurensia Y, et al. Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma. Leukemia [Internet]. 2018;32(5):1147-56 Available from: http://www.nature.com/articles/s41375-017-0004-x. [cited 7 Oct 2018].
32. Woessner R, Sah V, McCoon P, Grosskurth S, Deng N, DuPont R, et al. Inhibition of STAT3 by antisense oligonucleotide treatment decreases the immune suppressive tumor microenvironment in syngeneic and GEM tumor models [abstract]. In: Proceedings of the 110th Annual Meeting of the American Association for Cancer Research; 2017 Apr 1-5. Washington DC and Philadephia: AACR; 2017. p. Abstract nr 3684.
33. Yang Z-Z, Grote DM, Xiu B, Ziesmer SC, Price-Troska TL, Hodge LS, et al. TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma. Leukemia [Internet]. 2014;28(9):1872-84 Available from: http://www.ncbi.nlm.nih.gov/pubmed/24569779. [cited 7 Oct 2018].
34. Horikawa N, Abiko K, Matsumura N, Hamanishi J, Baba T, Yamaguchi K, et al. Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells. Clin Cancer Res [Internet]. 2017;23(2):587-99 Available from: http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-16-0387. [cited 21 Nov 2017].
35. Sade-Feldman M, Kanterman J, Klieger Y, Ish-Shalom E, Olga M, Saragovi A, et al. Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab. Clin Cancer Res [Internet]. 2016;22(23):5661-72 Available from: http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-15-3104. [cited 21 Nov 2017].
36. Jayaraman P, Parikh F, Lopez-Rivera E, Hailemichael Y, Clark A, Ma G, et al. Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. J Immunol [Internet]. 2012;188(11):5365-76 Available from: http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.1103553. [cited 21 Nov 2017].
37. Rosborough BR, Mathews LR, Matta BM, Liu Q, Raïch-Regué D, Thomson AW, et al. Cutting edge: Flt3 ligand mediates STAT3-independent expansion but STAT3-dependent activation of myeloid-derived suppressor cells. J Immunol [Internet]. 2014;192(8):3470-3 Available from: http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.1300058. [cited 21 Nov 2017].